Morgan Stanley Maintains Doximity(DOCS.US) With Hold Rating, Raises Target Price to $60
Doximity Is Maintained at Equal-Weight by Morgan Stanley
Morgan Stanley Maintains Equal-Weight on Doximity, Lowers Price Target to $60
Doximity Analyst Ratings
Doximity's Hold Rating: Navigating Uncertainty Amid Macroeconomic Risks and Industry Dynamics
KeyBanc Maintains Doximity(DOCS.US) With Buy Rating, Raises Target Price to $70
Keybanc Maintains Overweight on Doximity, Lowers Price Target to $70
Truist Financial Maintains Doximity(DOCS.US) With Hold Rating, Announces Target Price $58
Doximity Is Maintained at Hold by Truist Securities
Doximity Analyst Ratings
Truist Cuts Price Target on Doximity to $58 From $65, Keeps Hold Rating
Wells Fargo Upgrades Doximity(DOCS.US) to Hold Rating, Raises Target Price to $55
Analysts Have Conflicting Sentiments on These Healthcare Companies: Doximity (DOCS) and Diaceutics (OtherDIUXF)
Leerink Partners Maintains Doximity(DOCS.US) With Buy Rating, Maintains Target Price $90
Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI), Ardent Health Partners, Inc. (ARDT) and Doximity (DOCS)
Baird Maintains Doximity(DOCS.US) With Buy Rating, Raises Target Price to $87
Jefferies Maintains Doximity(DOCS.US) With Buy Rating, Raises Target Price to $88
Doximity Analyst Ratings
Leerink Partners Maintains Doximity(DOCS.US) With Buy Rating, Maintains Target Price $90
Doximity Price Target Raised to $65.00/Share From $55.00 by Mizuho